Skip to main content

Table 3 The predicted T helper cells epitopes, their antigenicity, allergenicity, toxicity and the population coverage from spike S protein and orf1ab polyprotein

From: Vaccinomic approach for novel multi epitopes vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)

Protein Core peptide (Epitope) Peptide Start End Vaxijen antigenicity (0.4) Allergenicity Toxicity Population coverage
Spike S protein FELLHAPAT FELLHAPATVCGPKK 515 529 0.5409 Nonallergen Nontoxin 98.03%
aFAMQMAYRF FAMQMAYRFNGIGVT 898 912 1.0278 Nonallergen Nontoxin 98.93%
FNFSQILPD FNFSQILPDPSKPSK 800 814 0.5831 Nonallergen Nontoxin 99.73%
FGAISSVLN FGAISSVLNDILSRL 970 984 0.5435 Nonallergen Nontoxin 98.66%
FNATRFASV FNATRFASVYAWNRK 342 356 0.5609 Nonallergen Nontoxin 99.23%
LLFNKVTLA LLFNKVTLADAGFIK 821 835 0.615 Nonallergen Nontoxin 99.48%
LLQYGSFCT LLQYGSFCTQLNRAL 753 767 0.8188 Nonallergen Nontoxin 99.21%
NRALTGIAV NRALTGIAVEQDKNT 764 778 0.5302 Nonallergen Nontoxin 99.03%
WTFGAGAAL WTFGAGAALQIPFAM 886 900 0.4918 Nonallergen Nontoxin 99.29%
orf1ab aVMYASAVVL VMYASAVVLLILMTA 3683 3697 0.4778 Nonallergen Nontoxin 98.28%
aFLLPSLATV FLLPSLATVAYFNMV 3639 3653 0.5954 Nonallergen Nontoxin 94.69%
aSLENVAFNV SLENVAFNVVNKGHF 6453 6467 1.0488 Nonallergen Nontoxin 97.84%
FFYVLGLAA FFYVLGLAAIMQLFF 2337 2351 0.8102 Nonallergen Nontoxin 99.72%
YELQTPFEI YELQTPFEIKLAKKF 249 263 0.5468 Nonallergen Nontoxin 98.88%
LIYSTAALG LIYSTAALGVLMSNL 2243 2257 0.5328 Nonallergen Nontoxin 99.77%
LRGTAVMSL LRGTAVMSLKEGQIN 7052 7066 0.8822 Nonallergen Nontoxin 99.82%
LVQMAPISA LVQMAPISAMVRMYI 2371 2385 1.0016 Nonallergen Nontoxin 99.86%
LVQSTQWSL LVQSTQWSLFFFLYE 3594 3608 1.095 Nonallergen Nontoxin 99.22%
PLIVTALRA PLIVTALRANSAVKL 4125 4139 0.9545 Nonallergen Nontoxin 99.70%
VLGLAAIMQ VLGLAAIMQLFFSYF 2340 2354 0.6624 Nonallergen Nontoxin 99.71%
SACVLAAEC SACVLAAECTIFKDA 2911 2925 0.5526 Nonallergen Nontoxin 93.56%
YVLGLAAIM YVLGLAAIMQLFFSY 2339 2353 0.6002 Nonallergen Nontoxin 99.87%
  1. athe overlapped epitopes between MHCI and MHCII molecules were used once in the vaccine construct as MHCI or MHCII epitopes
Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us